Germany's Bundesinstitut fur Arzneimittel und Medizinproduckte has prolonged a restriction on the use of low-dose oral contraceptives (Marketletters passim) until January 1, 1997. The move, comments a report from Reuters, "marks another twist in a protracted controversy stemming from the release of a British medical report last November saying low-dosage pills - containing desogestrel or gestodene - double the chance of developing blood clots."
The German decision, announced one day after a six-month directive expired, was taken after drug companies failed to present conclusive evidence that these pills are safe, and because European health officials demanded more tests, German officials have said. They have now called on all the OC pill makers to present a complete analysis of their findings within three months.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze